Clinical trials: Influenza, completed
Influenza
A Study to Evaluate Safety and Immunogenicity of FluvalAB-like Influenza Vaccine in Non-Elderly Adult and Elderly Subjects
The purpose of this study is to determine the immunogenicity and tolerability of one 0.5 mL intramuscular (IM) injection of FLUVAL AB-like trivalent influenza vaccine containing 6μgHA of seasonal A/H1N1, A/H3N2 and B influenza…
- Trial name
- NCT01459276
- Testing
- Vaccination with FAB-6011, Vaccination with FluvalAB
- Where
- 7 sites in Hungary
- Volunteers
- 1,206 people, healthy volunteers welcome
- Sponsor
- Fluart Innovative Vaccine Ltd, Hungary
Influenza
Safety and Immune Response of Candidate H1N1 Influenza Vaccines GSK2340274A and GSK234072A in Children 3 to Less Than 10 Years Old
This study is designed to characterize the safety and immunogenicity of pandemic influenza (H1N1) candidate vaccines GSK2340274A and GSK234072A in children 3 to less than 10 years old.
- Trial name
- NCT01161160
- Testing
- GSK Biologicals' GSK2340274A (two different formulations), GSK Biologicals' - GSK2340272A
- Where
- 2 sites in Philippines, Thailand
- Volunteers
- 209 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Systemic Lupus, Sjogren's Syndrome
Evaluation of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases
Studies in the literature have shown reduced effectiveness of influenza A (H3N2) virus vaccine (20-40%) when compared to A (H1N1) and influenza B.
- Trial name
- NCT03540823
- Testing
- Inactivated and fragmented influenza vaccine (A / Michigan / 45/2015 (H1N1) pdm09-like virus, A / Singapore / INFIMH-16-0019 / 2016 (H3N2) -like virus; B / Phuket / 3073/2013-like virus)
- Where
- Brazil
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
Influenza, Acute Upper Respiratory Infection
Treatment of Influenza in Routine Clinical Practice
This study evaluates the statistics of influenza and acute respiratory viral infections (ARVI) management in outpatient sites in Russia, Armenia, Moldova and Georgia (epidemiology: disease severity and bacterial exacerbations…
- Trial name
- FLU-EE (NCT02983019)
- Testing
- Kagocel
- Where
- 4 sites in Armenia, Georgia and 2 more
- Volunteers
- 18,946 people
- Sponsor
- Nearmedic Plus LLC
Influenza
Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older
The purpose of this placebo controlled study is to evaluate the safety and immunogenicity of different formulations of GSK Biologicals H7N1 influenza vaccine in subjects 65 years of age and older.
- Trial name
- NCT01949090
- Testing
- Investigational H7N1 vaccine GSK2789869A
- Where
- 8 sites in United States, Canada
- Volunteers
- 363 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With (TIV)
The purpose of this study is to describe the level of serum antibody conferred by CAIV-T and TIV against homotypic and heterotypic influenza virus strains.
- Trial name
- NCT00111579
- Testing
- CAIV-T, TIV
- Where
- 5 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza, Human, Acute Respiratory Infection
Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Patients 13-17 y.o.
The purpose of this study is to determine whether Ingavirin ® dosed 60 mg daily is effective and safe in the treatment of influenza and other acute respiratory viral infections in 13-17 years old patients.
- Conditions
- Influenza, Human, Acute Respiratory Infection, Viral Infection, Common Cold
- Trial name
- NCT03206346
- Testing
- Ingavirin
- Where
- 5 sites in Russia
- Volunteers
- 161 people
- Sponsor
- Valenta Pharm JSC
Influenza, Virus Diseases
Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study B)
Avian influenza (AI), also known as bird flu, has become a major public health concern in many regions of the world. The purpose of this study is to evaluate the safety of and immune response to an AI vaccine in healthy adults.
- Trial name
- NCT00380237
- Testing
- H9N2 (6-2) AA ca Reassortant (A/Chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Diabetes Mellitus, Type 2, Influenza
Information-Based Interventions for Influenza Vaccination Among Older Adults With Diabetes in Yangzhou, China
Influenza can cause serious illness in older adults, particularly those with diabetes. Although influenza vaccination is an important preventive measure, vaccination uptake among older adults in China remains low.
- Trial name
- NCT07901673
- Testing
- Standard Information Intervention, Gain-Framed Information Intervention, Loss-Framed Information Intervention
- Where
- 4 sites in China
- Volunteers
- 759 people
- Sponsor
- Southeast University, China
Influenza
H5N1 Priming and Boosting Strategies
Severe disease in humans due to bird influenza viruses (H5N1) has led to concern that this virus may result in a widespread outbreak of bird flu.
- Trial name
- NCT00703053
- Testing
- A/Vietnam/1203/04, A/Indonesia/05/05
- Where
- 5 sites in United States
- Volunteers
- 505 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model
A Phase 2, single center, randomized, double blind study evaluating the safety, efficacy, and immunogenicity of MVA NP+M1 in the H3N2 human influenza challenge model; on healthy adult volunteers.
- Trial name
- NCT03883113
- Testing
- MVA-NP+M1, Saline, H3N2 (A/Belgium/2417/2015)
- Where
- Belgium
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Barinthus Biotherapeutics
Influenza, Human
Phase1 Study of GR121167, Single and Multiple Dose Study in Healthy Japanese Males
This study is a randomized, double-blind, ascending dose, placebo-controlled, incomplete crossover, single and multiple dose study in healthy Japanese male subjects to assess the pharmacokinetics and safety/tolerability of single…
- Trial name
- NCT01428479
- Testing
- GR121167 Solution
- Where
- Japan
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Tract Infections, Influenza
Trial of Vitamin D Supplementation for the Prevention of Influenza and Other Respiratory Infections (ViDiFlu)
Purpose: The study null hypothesis is that vitamin D supplementation will not influence time to acute respiratory tract infection in sheltered accommodation residents.
- Trial name
- ViDiFlu (NCT01069874)
- Testing
- Cholecalciferol (Vitamin D/Vigantol oil), Miglyol oil
- Where
- 2 sites in United Kingdom
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Barts & The London NHS Trust
Influenza
T and B Cell Response to Avian Flu Vaccine
The purpose of this substudy study is to evaluate the types of cells involved in fighting infection to the A/H5N1 (avian flu virus) vaccine.
- Trial name
- NCT00337896
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Clinical Trial to Evaluate the Immunogenicity and Safety of an Adjuvanted A(H1N1)v Influenza Vaccine and a Non-adjuvanted A(H1N1)v Influenza Vaccine in HIV-infected Patients (ANRS 151 Hifluvac)
A 1-year multicenter, randomized, single-blinded, phase II trial, stratified on HAART. The purpose of this trial is to evaluate the immunogenicity and safety of a A(H1N1)French National Agency for Research on AIDS and Viral…
- Trial name
- NCT01008813
- Testing
- adjuvanted A(H1N1)v influenza vaccine, non-adjuvanted A(H1N1)v influenza vaccine
- Where
- 6 sites in France
- Volunteers
- 306 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Influenza, Herpes Zoster
Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHINGRIX)
Vaccines are used to prevent infectious diseases worldwide. Unfortunately, many vaccines, like the flu vaccine, are less effective in older adults.
- Trial name
- NCT05082688
- Testing
- Herpes zoster vaccination (Shingrix, GSK), Influenza Vaccine (Fluarix Tetra Northern Hemisphere 2021 or 2022, GSK)
- Where
- Netherlands
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
SARS CoV 2 Infection, Influenza, Human
A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19
This is a Phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX® when coadministered with seasonal surface antigen inactivated adjuvanted influenza vaccine (SIIV) in adults…
- Trial name
- NCT05981846
- Testing
- BIMERVAX, SIIV
- Where
- 8 sites in Spain
- Volunteers
- 279 people, healthy volunteers welcome
- Sponsor
- Hipra Scientific, S.L.U
Seasonal Influenza B
Assessment of an Oral Influenza B Vaccine Tablet (VXA-BYW.10) Following Single Dose Administration in Healthy Adults
This is a phase 1, single-center, placeb-controlled, double-blind study. The purpose of this study is to determine the safety and immunogenicity of an oral vaccine tablet to prevent seasonal influenza B tested at two dose levels…
- Trial name
- NCT02547792
- Testing
- VXA-BYW.10 (Low Dose) Oral Vaccine, VXA-BYW.10 (High Dose) Oral Vaccine
- Where
- New Zealand
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Vaxart
Influenza
Assess the Risk of Solid Organ Transplant Rejection Following Vaccination With Pandemrix™ in UK
This study aims to assess the risk of solid organ transplant (SOT) rejection following vaccination with Pandemrix™ and/ or seasonal influenza vaccination.
- Trial name
- NCT01715792
- Testing
- Data collection
- Where
- United Kingdom
- Volunteers
- 587 people
- Sponsor
- GlaxoSmithKline
Healthy
Safety and Tolerability of a Cell-Derived Influenza Vaccine in Healthy Adults Aged ≥18 Years and ≤ 49 Years
A controlled, double blinded study to determine the safety and reactogenicity in healthy adults of a single dose of a trivalent cell-derived influenza vaccine administered by intramuscular injection.
- Trial name
- NCT00599443
- Testing
- Seasonal cell-derived influenza vaccine
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Solvay Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.